Treatment-related symptoms during the first year following transperineal (125)I prostate implantation Journal Article
| Authors: | Kleinberg, L.; Wallner, K.; Roy, J.; Zelefsky, M.; Arterbery, V. E.; Fuks, Z.; Harrison, L. |
| Article Title: | Treatment-related symptoms during the first year following transperineal (125)I prostate implantation |
| Abstract: | Purpose: To summarize the urinary, rectal, and sexual symptoms occuring during the first 12 months following 125I prostatic implantation. Methods and Materials: Thirty-one patients with Stage T1 or T2 prostatic carcinoma were evaluated for morbidity following computed tomography-guided transperineal 1251 implants from 1988 to 1991. The median total activity used was 47 mCi (range 35-73 mCi). Toxicity was evaluated using a modification of the Radiation Therapy Oncology Group grading system. Results: Nocturia was the most common treatment-related symptom, reported by 80% of patients within 2 months after implantation, and persisted at 12 months in 45% of the patients. Mild dysuria developed in 48% of patients within 2 months of implantation; two patients needed analgesics for their dysuria. Terazosin hydrochloride (2-10 mg qd) provided subjective improvement of urinary symptoms in seven of eight patients in whom it was tried. Rectal urgency, soft stools, and increased frequency of bowel movements was reported by 25% of the patients within 1-2 months after implantation. The incidence of assymptomatic rectal bleeding or ulceration occurring at any time after implantation was 47%, but resolved in all patients with expectant treatment. Self-limited ulceration of the rectal mucosal occurred in 16%, but only one patient developed a prostato-rectal fistula, managed with an ileal conduit. Five of the 18 potent patients experienced discomfort on erection or ejaculation, beginning within several weeks of their implant. The discomfort resolved within 6 months in three of the patients, but persisted for 18 and 24 months in the other two. Conclusion: 125I implantation, as performed in this series, is generally associated with only mild-moderate genitourinary and rectal symptoms that may persist 6 months or more after implantation. Prostatic carcinoma, Brachytherapy, Morbidity. © 1994. |
| Keywords: | adult; clinical article; aged; aged, 80 and over; implant; clinical trial; morbidity; tomography, x-ray computed; prostatic neoplasms; sexual dysfunction; kidney; iodine 125; iodine radioisotopes; radioactivity; brachytherapy; radiotherapy planning, computer-assisted; radioisotope therapy; dysuria; prostate carcinoma; rectum; perineum; middle age; rectum disease; nocturia; human; male; priority journal; article; support, non-u.s. gov't; sex behavior |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 28 |
| Issue: | 4 |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1994-03-01 |
| Start Page: | 985 |
| End Page: | 990 |
| Language: | English |
| DOI: | 10.1016/0360-3016(94)90119-8 |
| PROVIDER: | scopus |
| PUBMED: | 8138452 |
| DOI/URL: | |
| Notes: | Export Date: 14 January 2019 -- Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work